APO Research
Talk to an analyst

APO RESEARCH · REPORT

Immune Checkpoint Agents

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Immune Checkpoint Agents Industry Growth and Trends Forecast to 2032

26 December 202577 pages

Choose your research edition.

Industry ResearchImmune Checkpoint Agents Industry Research Report 2026108 pages · $2,950 USDIndustry Growth & TrendsGlobal Immune Checkpoint Agents Industry Growth and Trends Forecast to 203277 pages · $3,450 USDMarket StructureGlobal Immune Checkpoint Agents Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032174 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Immune Checkpoint Agents Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Immune Checkpoint Agents Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Immune Checkpoint Agents market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Immune Checkpoint Agents is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Immune Checkpoint Agents is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Immune Checkpoint Agents is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Immune Checkpoint Agents include Bristol Myers Squibb, AstraZeneca, Roche and Merck, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Immune Checkpoint Agents market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Immune Checkpoint Agents market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Immune Checkpoint Agents market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Immune Checkpoint Agents.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Immune Checkpoint Agents market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Immune Checkpoint Agents Market by Company

Bristol Myers Squibb

AstraZeneca

Roche

Merck

Immune Checkpoint Agents Segment by Type

Anti-PD-L1 Drug

Anti-PD-1 Drug

CTLA4

Immune Checkpoint Agents Segment by Application

Lung Cancer

Melanoma

Colorectal Cancer

Prostate Cancer

BreastCancer

Blood Cancers

Immune Checkpoint Agents Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Immune Checkpoint Agents market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Immune Checkpoint Agents and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Immune Checkpoint Agents.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Immune Checkpoint Agents manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Immune Checkpoint Agents in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Anti-PD-L1 Drug Table 2. Major Company of Anti-PD-1 Drug Table 3. Major Company of CTLA4 Table 4. Global Immune Checkpoint Agents Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Immune Checkpoint Agents Sales by Type (2021-2026) & (K Units) Table 6. Global Immune Checkpoint Agents Sales Market Share in Volume by Type (2021-2026) Table 7. Global Immune Checkpoint Agents Sales by Type (2021-2026) & (US$ Million) Table 8. Global Immune Checkpoint Agents Sales Market Share in Value by Type (2021-2026) Table 9. Global Immune Checkpoint Agents Price by Type (2021-2026) & (US$/Unit) Table 10. Global Immune Checkpoint Agents Sales by Type (2027-2032) & (K Units) Table 11. Global Immune Checkpoint Agents Sales Market Share in Volume by Type (2027-2032) Table 12. Global Immune Checkpoint Agents Sales by Type (2027-2032) & (US$ Million) Table 13. Global Immune Checkpoint Agents Sales Market Share in Value by Type (2027-2032) Table 14. Global Immune Checkpoint Agents Price by Type (2027-2032) & (US$/Unit) Table 15. North America Immune Checkpoint Agents Sales by Type (2021-2026) & (K Units) Table 16. North America Immune Checkpoint Agents Sales by Type (2021-2026) & (US$ Million) Table 17. Europe Immune Checkpoint Agents Sales by Type (2021-2026) & (K Units) Table 18. Europe Immune Checkpoint Agents Sales by Type (2021-2026) & (US$ Million) Table 19. Asia-Pacific Immune Checkpoint Agents Sales by Type (2021-2026) & (K Units) Table 20. Asia-Pacific Immune Checkpoint Agents Sales by Type (2021-2026) & (US$ Million) Table 21. Latin America Immune Checkpoint Agents Sales by Type (2021-2026) & (K Units) Table 22. Latin America Immune Checkpoint Agents Sales by Type (2021-2026) & (US$ Million) Table 23. Middle East and Africa Immune Checkpoint Agents Sales by Type (2021-2026) & (K Units) Table 24. Middle East and Africa Immune Checkpoint Agents Sales by Type (2021-2026) & (US$ Million) Table 25. Immune Checkpoint Agents Industry Trends Table 26. Immune Checkpoint Agents Industry Drivers Table 27. Immune Checkpoint Agents Industry Opportunities and Challenges Table 28. Immune Checkpoint Agents Industry Restraints Table 29. Global Immune Checkpoint Agents Sales Revenue by Company (US$ Million) & (2021-2026) Table 30. Global Immune Checkpoint Agents Revenue Market Share by Company (2021-2026) Table 31. Global Immune Checkpoint Agents Sales by Company (2021-2026) & (K Units) Table 32. Global Immune Checkpoint Agents Sales Share by Company (2021-2026) Table 33. Global Immune Checkpoint Agents Market Price by Company (2021-2026) & (US$/Unit) Table 34. Global Immune Checkpoint Agents Industry Company Ranking, 2024 VS 2025 VS 2026 Table 35. Global Immune Checkpoint Agents Major Company Production Sites and Headquarters Table 36. Global Immune Checkpoint Agents Company, Product Type & Application Table 37. Global Immune Checkpoint Agents Company Establishment Date Table 38. Global Company Market Concentration Ratio (CR5 and HHI) Table 39. Global Immune Checkpoint Agents by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 40. Global Immune Checkpoint Agents Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 41. Global Immune Checkpoint Agents Sales by Region (2021-2026) & (K Units) Table 42. Global Immune Checkpoint Agents Sales Market Share in Volume by Region (2021-2026) Table 43. Global Immune Checkpoint Agents Sales by Region (2021-2026) & (US$ Million) Table 44. Global Immune Checkpoint Agents Sales Market Share in Value by Region (2021-2026) Table 45. Global Immune Checkpoint Agents Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Global Immune Checkpoint Agents Sales by Region (2027-2032) & (K Units) Table 47. Global Immune Checkpoint Agents Sales Market Share in Volume by Region (2027-2032) Table 48. Global Immune Checkpoint Agents Sales by Region (2027-2032) & (US$ Million) Table 49. Global Immune Checkpoint Agents Sales Market Share in Value by Region (2027-2032) Table 50. Global Immune Checkpoint Agents Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 51. Global Immune Checkpoint Agents Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 52. Global Immune Checkpoint Agents Sales by Application (2021-2026) & (K Units) Table 53. Global Immune Checkpoint Agents Sales Market Share in Volume by Application (2021-2026) Table 54. Global Immune Checkpoint Agents Sales by Application (2021-2026) & (US$ Million) Table 55. Global Immune Checkpoint Agents Sales Market Share in Value by Application (2021-2026) Table 56. Global Immune Checkpoint Agents Price by Application (2021-2026) & (US$/Unit) Table 57. Global Immune Checkpoint Agents Sales by Application (2027-2032) & (K Units) Table 58. Global Immune Checkpoint Agents Sales Market Share in Volume by Application (2027-2032) Table 59. Global Immune Checkpoint Agents Sales by Application (2027-2032) & (US$ Million) Table 60. Global Immune Checkpoint Agents Sales Market Share in Value by Application (2027-2032) Table 61. Global Immune Checkpoint Agents Price by Application (2027-2032) & (US$/Unit) Table 62. North America Immune Checkpoint Agents Sales by Application (2021-2026) & (K Units) Table 63. North America Immune Checkpoint Agents Sales by Application (2021-2026) & (US$ Million) Table 64. Europe Immune Checkpoint Agents Sales by Application (2021-2026) & (K Units) Table 65. Europe Immune Checkpoint Agents Sales by Application (2021-2026) & (US$ Million) Table 66. Asia-Pacific Immune Checkpoint Agents Sales by Application (2021-2026) & (K Units) Table 67. Asia-Pacific Immune Checkpoint Agents Sales by Application (2021-2026) & (US$ Million) Table 68. Latin America Immune Checkpoint Agents Sales by Application (2021-2026) & (K Units) Table 69. Latin America Immune Checkpoint Agents Sales by Application (2021-2026) & (US$ Million) Table 70. Middle East and Africa Immune Checkpoint Agents Sales by Application (2021-2026) & (K Units) Table 71. Middle East and Africa Immune Checkpoint Agents Sales by Application (2021-2026) & (US$ Million) Table 72. Bristol Myers Squibb Company Information Table 73. Bristol Myers Squibb Business Overview Table 74. Bristol Myers Squibb Immune Checkpoint Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Bristol Myers Squibb Immune Checkpoint Agents Product Portfolio Table 76. Bristol Myers Squibb Recent Development Table 77. AstraZeneca Company Information Table 78. AstraZeneca Business Overview Table 79. AstraZeneca Immune Checkpoint Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. AstraZeneca Immune Checkpoint Agents Product Portfolio Table 81. AstraZeneca Recent Development Table 82. Roche Company Information Table 83. Roche Business Overview Table 84. Roche Immune Checkpoint Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Roche Immune Checkpoint Agents Product Portfolio Table 86. Roche Recent Development Table 87. Merck Company Information Table 88. Merck Business Overview Table 89. Merck Immune Checkpoint Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Merck Immune Checkpoint Agents Product Portfolio Table 91. Merck Recent Development Table 92. North America Immune Checkpoint Agents Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 93. North America Immune Checkpoint Agents Sales by Country (2021-2026) & (K Units) Table 94. North America Immune Checkpoint Agents Sales Market Share by Country (2021-2026) Table 95. North America Immune Checkpoint Agents Sales Forecast by Country (2027-2032) & (K Units) Table 96. North America Immune Checkpoint Agents Sales Market Share Forecast by Country (2027-2032) Table 97. North America Immune Checkpoint Agents Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 98. North America Immune Checkpoint Agents Market Size by Country (2021-2026) & (US$ Million) Table 99. North America Immune Checkpoint Agents Market Share by Country (2021-2026) Table 100. North America Immune Checkpoint Agents Market Size Forecast by Country (2027-2032) & (US$ Million) Table 101. North America Immune Checkpoint Agents Market Share Forecast by Country (2027-2032) Table 102. Europe Immune Checkpoint Agents Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 103. Europe Immune Checkpoint Agents Sales by Country (2021-2026) & (K Units) Table 104. Europe Immune Checkpoint Agents Sales Market Share by Country (2021-2026) Table 105. Europe Immune Checkpoint Agents Sales Forecast by Country (2027-2032) & (K Units) Table 106. Europe Immune Checkpoint Agents Sales Market Share Forecast by Country (2027-2032) Table 107. Europe Immune Checkpoint Agents Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 108. Europe Immune Checkpoint Agents Market Size by Country (2021-2026) & (US$ Million) Table 109. Europe Immune Checkpoint Agents Market Share by Country (2021-2026) Table 110. Europe Immune Checkpoint Agents Market Size Forecast by Country (2027-2032) & (US$ Million) Table 111. Europe Immune Checkpoint Agents Market Share Forecast by Country (2027-2032) Table 112. Asia-Pacific Immune Checkpoint Agents Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 113. Asia-Pacific Immune Checkpoint Agents Sales by Country (2021-2026) & (K Units) Table 114. Asia-Pacific Immune Checkpoint Agents Sales Market Share by Country (2021-2026) Table 115. Asia-Pacific Immune Checkpoint Agents Sales Forecast by Country (2027-2032) & (K Units) Table 116. Asia-Pacific Immune Checkpoint Agents Sales Market Share Forecast by Country (2027-2032) Table 117. Asia-Pacific Immune Checkpoint Agents Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 118. Asia-Pacific Immune Checkpoint Agents Market Size by Country (2021-2026) & (US$ Million) Table 119. Asia-Pacific Immune Checkpoint Agents Market Share by Country (2021-2026) Table 120. Asia-Pacific Immune Checkpoint Agents Market Size Forecast by Country (2027-2032) & (US$ Million) Table 121. Asia-Pacific Immune Checkpoint Agents Market Share Forecast by Country (2027-2032) Table 122. Latin America Immune Checkpoint Agents Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 123. Latin America Immune Checkpoint Agents Sales by Country (2021-2026) & (K Units) Table 124. Latin America Immune Checkpoint Agents Sales Market Share by Country (2021-2026) Table 125. Latin America Immune Checkpoint Agents Sales Forecast by Country (2027-2032) & (K Units) Table 126. Latin America Immune Checkpoint Agents Sales Market Share Forecast by Country (2027-2032) Table 127. Latin America Immune Checkpoint Agents Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 128. Latin America Immune Checkpoint Agents Market Size by Country (2021-2026) & (US$ Million) Table 129. Latin America Immune Checkpoint Agents Market Share by Country (2021-2026) Table 130. Latin America Immune Checkpoint Agents Market Size Forecast by Country (2027-2032) & (US$ Million) Table 131. Latin America Immune Checkpoint Agents Market Share Forecast by Country (2027-2032) Table 132. Middle East and Africa Immune Checkpoint Agents Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 133. Middle East and Africa Immune Checkpoint Agents Sales by Country (2021-2026) & (K Units) Table 134. Middle East and Africa Immune Checkpoint Agents Sales Market Share by Country (2021-2026) Table 135. Middle East and Africa Immune Checkpoint Agents Sales Forecast by Country (2027-2032) & (K Units) Table 136. Middle East and Africa Immune Checkpoint Agents Sales Market Share Forecast by Country (2027-2032) Table 137. Middle East and Africa Immune Checkpoint Agents Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 138. Middle East and Africa Immune Checkpoint Agents Market Size by Country (2021-2026) & (US$ Million) Table 139. Middle East and Africa Immune Checkpoint Agents Market Share by Country (2021-2026) Table 140. Middle East and Africa Immune Checkpoint Agents Market Size Forecast by Country (2027-2032) & (US$ Million) Table 141. Middle East and Africa Immune Checkpoint Agents Market Share Forecast by Country (2027-2032) Table 142. Key Raw Materials Table 143. Raw Materials Key Suppliers Table 144. Immune Checkpoint Agents Distributors List Table 145. Immune Checkpoint Agents Customers List Table 146. Research Programs/Design for This Report Table 147. Authors List of This Report Table 148. Secondary Sources Table 149. Primary Sources List of Figures Figure 1. Immune Checkpoint Agents Image Figure 2. Global Immune Checkpoint Agents Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Immune Checkpoint Agents Market Size (2021-2032) & (US$ Million) Figure 4. Global Immune Checkpoint Agents Sales (2021-2032) & (K Units) Figure 5. Anti-PD-L1 Drug Image Figure 6. Global Anti-PD-L1 Drug Sales YoY Growth (2021-2032) & (K Units) Figure 7. Anti-PD-1 Drug Image Figure 8. Global Anti-PD-1 Drug Sales YoY Growth (2021-2032) & (K Units) Figure 9. CTLA4 Image Figure 10. Global CTLA4 Sales YoY Growth (2021-2032) & (K Units) Figure 11. Global Immune Checkpoint Agents Market Size Overview by Type (2021-2032) & (US$ Million) Figure 12. Global Immune Checkpoint Agents Market Share by Type 2025 VS 2032 Figure 13. North America Immune Checkpoint Agents Sales Market Share in Volume by Type in 2025 Figure 14. North America Immune Checkpoint Agents Sales Market Share in Value by Type in 2025 Figure 15. Europe Immune Checkpoint Agents Sales Market Share in Volume by Type in 2025 Figure 16. Europe Immune Checkpoint Agents Sales Market Share in Value by Type in 2025 Figure 17. Asia-Pacific Immune Checkpoint Agents Sales Market Share in Volume by Type in 2025 Figure 18. Asia-Pacific Immune Checkpoint Agents Sales Market Share in Value by Type in 2025 Figure 19. Latin America Immune Checkpoint Agents Sales Market Share in Volume by Type in 2025 Figure 20. Latin America Immune Checkpoint Agents Sales Market Share in Value by Type in 2025 Figure 21. Middle East and Africa Immune Checkpoint Agents Sales Market Share in Volume by Type in 2025 Figure 22. Middle East and Africa Immune Checkpoint Agents Sales Market Share in Value by Type in 2025 Figure 23. Global Top 5 and 10 Immune Checkpoint Agents Players Market Share by Revenue in 2025 Figure 24. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 25. Lung Cancer Image Figure 26. Global Lung Cancer Sales YoY Growth (2021-2032) & (K Units) Figure 27. Melanoma Image Figure 28. Global Melanoma Sales YoY Growth (2021-2032) & (K Units) Figure 29. Colorectal Cancer Image Figure 30. Global Colorectal Cancer Sales YoY Growth (2021-2032) & (K Units) Figure 31. Prostate Cancer Image Figure 32. Global Prostate Cancer Sales YoY Growth (2021-2032) & (K Units) Figure 33. BreastCancer Image Figure 34. Global BreastCancer Sales YoY Growth (2021-2032) & (K Units) Figure 35. Blood Cancers Image Figure 36. Global Blood Cancers Sales YoY Growth (2021-2032) & (K Units) Figure 37. Global Immune Checkpoint Agents Market Size Overview by Application (2021-2032) & (US$ Million) Figure 38. Global Immune Checkpoint Agents Market Share by Application 2025 VS 2032 Figure 39. North America Immune Checkpoint Agents Sales Market Share in Volume by Application in 2025 Figure 40. North America Immune Checkpoint Agents Sales Market Share in Value by Application in 2025 Figure 41. Europe Immune Checkpoint Agents Sales Market Share in Volume by Application in 2025 Figure 42. Europe Immune Checkpoint Agents Sales Market Share in Value by Application in 2025 Figure 43. Asia-Pacific Immune Checkpoint Agents Sales Market Share in Volume by Application in 2025 Figure 44. Asia-Pacific Immune Checkpoint Agents Sales Market Share in Value by Application in 2025 Figure 45. Latin America Immune Checkpoint Agents Sales Market Share in Volume by Application in 2025 Figure 46. Latin America Immune Checkpoint Agents Sales Market Share in Value by Application in 2025 Figure 47. Middle East and Africa Immune Checkpoint Agents Sales Market Share in Volume by Application in 2025 Figure 48. Middle East and Africa Immune Checkpoint Agents Sales Market Share in Value by Application in 2025 Figure 49. North America Immune Checkpoint Agents Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 50. North America Immune Checkpoint Agents Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. North America Immune Checkpoint Agents Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. North America Immune Checkpoint Agents Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Europe Immune Checkpoint Agents Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 54. Europe Immune Checkpoint Agents Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Europe Immune Checkpoint Agents Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Europe Immune Checkpoint Agents Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Asia-Pacific Immune Checkpoint Agents Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 58. Asia-Pacific Immune Checkpoint Agents Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Asia-Pacific Immune Checkpoint Agents Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Asia-Pacific Immune Checkpoint Agents Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Latin America Immune Checkpoint Agents Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 62. Latin America Immune Checkpoint Agents Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Latin America Immune Checkpoint Agents Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Latin America Immune Checkpoint Agents Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Middle East and Africa Immune Checkpoint Agents Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 66. Middle East and Africa Immune Checkpoint Agents Sales Share by Country: 2021 VS 2025 VS 2032 Figure 67. Middle East and Africa Immune Checkpoint Agents Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 68. Middle East and Africa Immune Checkpoint Agents Market Share by Country: 2021 VS 2025 VS 2032 Figure 69. Immune Checkpoint Agents Value Chain Figure 70. Key Raw Materials Price Figure 71. Manufacturing Cost Structure Figure 72. Immune Checkpoint Agents Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • Anti-PD-L1 Drug
  • Anti-PD-1 Drug
  • CTLA4
Applications
  • Lung Cancer
  • Melanoma
  • Colorectal Cancer
  • Prostate Cancer
  • BreastCancer
  • Blood Cancers
Companies covered
  • Bristol Myers Squibb
  • AstraZeneca
  • Roche
  • Merck

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Immune Checkpoint Agents Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Immune Checkpoint Agents Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Immune Checkpoint Agents Market by Type
  6. 1.3.1 Anti-PD-L1 Drug
  7. 1.3.2 Anti-PD-1 Drug
  8. 1.3.3 CTLA4
  9. 1.4 Global Immune Checkpoint Agents Market Size by Type
  10. 1.4.1 Global Immune Checkpoint Agents Market Size Overview by Type (2021-2032)
  11. 1.4.2 Global Immune Checkpoint Agents Historic Market Size Review by Type (2021-2026)
  12. 1.4.3 Global Immune Checkpoint Agents Forecasted Market Size by Type (2027-2032)
  13. 1.5 Key Regions Market Size by Type
  14. 1.5.1 North America Immune Checkpoint Agents Sales Breakdown by Type (2021-2026)
  15. 1.5.2 Europe Immune Checkpoint Agents Sales Breakdown by Type (2021-2026)
  16. 1.5.3 Asia-Pacific Immune Checkpoint Agents Sales Breakdown by Type (2021-2026)
  17. 1.5.4 South America Immune Checkpoint Agents Sales Breakdown by Type (2021-2026)
  18. 1.5.5 Middle East and Africa Immune Checkpoint Agents Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Immune Checkpoint Agents Industry Trends
  2. 2.2 Immune Checkpoint Agents Industry Drivers
  3. 2.3 Immune Checkpoint Agents Industry Opportunities and Challenges
  4. 2.4 Immune Checkpoint Agents Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Immune Checkpoint Agents Revenue (2021-2026)
  2. 3.2 Global Top Players by Immune Checkpoint Agents Sales (2021-2026)
  3. 3.3 Global Top Players by Immune Checkpoint Agents Price (2021-2026)
  4. 3.4 Global Immune Checkpoint Agents Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Immune Checkpoint Agents Major Company Production Sites & Headquarters
  6. 3.6 Global Immune Checkpoint Agents Company, Product Type & Application
  7. 3.7 Global Immune Checkpoint Agents Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Immune Checkpoint Agents Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Immune Checkpoint Agents Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Immune Checkpoint Agents Tier 1, Tier 2, and Tier 3
4 Immune Checkpoint Agents Regional Status and Outlook
  1. 4.1 Global Immune Checkpoint Agents Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Immune Checkpoint Agents Historic Market Size by Region
  3. 4.2.1 Global Immune Checkpoint Agents Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Immune Checkpoint Agents Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Immune Checkpoint Agents Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Immune Checkpoint Agents Forecasted Market Size by Region
  7. 4.3.1 Global Immune Checkpoint Agents Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Immune Checkpoint Agents Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Immune Checkpoint Agents Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Immune Checkpoint Agents by Application
  1. 5.1 Immune Checkpoint Agents Market by Application
  2. 5.1.1 Lung Cancer
  3. 5.1.2 Melanoma
  4. 5.1.3 Colorectal Cancer
  5. 5.1.4 Prostate Cancer
  6. 5.1.5 BreastCancer
  7. 5.1.6 Blood Cancers
  8. 5.2 Global Immune Checkpoint Agents Market Size by Application
  9. 5.2.1 Global Immune Checkpoint Agents Market Size Overview by Application (2021-2032)
  10. 5.2.2 Global Immune Checkpoint Agents Historic Market Size Review by Application (2021-2026)
  11. 5.2.3 Global Immune Checkpoint Agents Forecasted Market Size by Application (2027-2032)
  12. 5.3 Key Regions Market Size by Application
  13. 5.3.1 North America Immune Checkpoint Agents Sales Breakdown by Application (2021-2026)
  14. 5.3.2 Europe Immune Checkpoint Agents Sales Breakdown by Application (2021-2026)
  15. 5.3.3 Asia-Pacific Immune Checkpoint Agents Sales Breakdown by Application (2021-2026)
  16. 5.3.4 South America Immune Checkpoint Agents Sales Breakdown by Application (2021-2026)
  17. 5.3.5 Middle East and Africa Immune Checkpoint Agents Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Bristol Myers Squibb
  2. 6.1.1 Bristol Myers Squibb Company Information
  3. 6.1.2 Bristol Myers Squibb Business Overview
  4. 6.1.3 Bristol Myers Squibb Immune Checkpoint Agents Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Bristol Myers Squibb Immune Checkpoint Agents Product Portfolio
  6. 6.1.5 Bristol Myers Squibb Recent Developments
  7. 6.2 AstraZeneca
  8. 6.2.1 AstraZeneca Company Information
  9. 6.2.2 AstraZeneca Business Overview
  10. 6.2.3 AstraZeneca Immune Checkpoint Agents Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 AstraZeneca Immune Checkpoint Agents Product Portfolio
  12. 6.2.5 AstraZeneca Recent Developments
  13. 6.3 Roche
  14. 6.3.1 Roche Company Information
  15. 6.3.2 Roche Business Overview
  16. 6.3.3 Roche Immune Checkpoint Agents Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Roche Immune Checkpoint Agents Product Portfolio
  18. 6.3.5 Roche Recent Developments
  19. 6.4 Merck
  20. 6.4.1 Merck Company Information
  21. 6.4.2 Merck Business Overview
  22. 6.4.3 Merck Immune Checkpoint Agents Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Merck Immune Checkpoint Agents Product Portfolio
  24. 6.4.5 Merck Recent Developments
7 North America by Country
  1. 7.1 North America Immune Checkpoint Agents Sales by Country
  2. 7.1.1 North America Immune Checkpoint Agents Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Immune Checkpoint Agents Sales by Country (2021-2026)
  4. 7.1.3 North America Immune Checkpoint Agents Sales Forecast by Country (2027-2032)
  5. 7.2 North America Immune Checkpoint Agents Market Size by Country
  6. 7.2.1 North America Immune Checkpoint Agents Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Immune Checkpoint Agents Market Size by Country (2021-2026)
  8. 7.2.3 North America Immune Checkpoint Agents Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Immune Checkpoint Agents Sales by Country
  2. 8.1.1 Europe Immune Checkpoint Agents Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Immune Checkpoint Agents Sales by Country (2021-2026)
  4. 8.1.3 Europe Immune Checkpoint Agents Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Immune Checkpoint Agents Market Size by Country
  6. 8.2.1 Europe Immune Checkpoint Agents Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Immune Checkpoint Agents Market Size by Country (2021-2026)
  8. 8.2.3 Europe Immune Checkpoint Agents Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Immune Checkpoint Agents Sales by Country
  2. 9.1.1 Asia-Pacific Immune Checkpoint Agents Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Immune Checkpoint Agents Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Immune Checkpoint Agents Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Immune Checkpoint Agents Market Size by Country
  6. 9.2.1 Asia-Pacific Immune Checkpoint Agents Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Immune Checkpoint Agents Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Immune Checkpoint Agents Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Immune Checkpoint Agents Sales by Country
  2. 10.1.1 South America Immune Checkpoint Agents Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Immune Checkpoint Agents Sales by Country (2021-2026)
  4. 10.1.3 South America Immune Checkpoint Agents Sales Forecast by Country (2027-2032)
  5. 10.2 South America Immune Checkpoint Agents Market Size by Country
  6. 10.2.1 South America Immune Checkpoint Agents Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Immune Checkpoint Agents Market Size by Country (2021-2026)
  8. 10.2.3 South America Immune Checkpoint Agents Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Immune Checkpoint Agents Sales by Country
  2. 11.1.1 Middle East and Africa Immune Checkpoint Agents Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Immune Checkpoint Agents Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Immune Checkpoint Agents Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Immune Checkpoint Agents Market Size by Country
  6. 11.2.1 Middle East and Africa Immune Checkpoint Agents Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Immune Checkpoint Agents Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Immune Checkpoint Agents Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Immune Checkpoint Agents Value Chain Analysis
  2. 12.1.1 Immune Checkpoint Agents Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Immune Checkpoint Agents Production Mode & Process
  7. 12.2 Immune Checkpoint Agents Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Immune Checkpoint Agents Distributors
  10. 12.2.3 Immune Checkpoint Agents Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst